P16INK4a as a progression/regression tumour marker in LSIL cervix lesions: our clinical experience.
CONCLUSION: p16l4a should help to identify which LSIL cases are inclined to the progression of the disease and focalize which patients are eligible for specific treatment.
PMID: 29787011 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
More News: Cancer & Oncology | Colposcopy | Cytology | OBGYN | Papanicolaou (Pap) Smear | Study | Women